Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Inclusion Criteria:

* Target and Period: Patients aged 18 or older
* Target Conditions:

  1. Lazertinib:

     * Patients diagnosed with locally progressive or metastatic non-small cell lung cancer, who previously received first or second-generation EGFR-TKI treatment, and who started administrating Lazertinib during the index period
     * Patients with T790M mutation positive
     * Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration
  2. Platinum-based Chemotherapy

     * Patients who were diagnosed with locally advanced or metastatic non-small cell lung cancer, and previously received first or second-generation EGFR-TKI treatment during the baseline period
     * Patient who started administering platinum-based chemotherapy after prior first or second-generation EGFR-TKI treatment during the index period
     * Patients who were confirmed positive for active EGFR mutations (L858R, Exon19Del, G719X, L861Q) during the baseline period
     * Patients with an ECOG PS score of 0 to 1 at the time of initial drug administration

Exclusion Criteria:

* Patients with carcinoma besides NSCLC requiring treatment
* Any unstable brain metastasis with symptomatic and/or requiring emergency treatment